Lilly Enters into Exclusive Licensing Agreement with Rigel Pharmaceuticals Accessing Promising RIPK1 Inhibitor
Eli Lilly and Co inked a deal to gain worldwide, exclusive licensing rights to the autoimmune and inflammatory disease treatment […]
NeuroGenesis and Hadassah Medical Center Report Significant Results in Patients with Progressive Multiple Sclerosis Treated with NG-01 Autologous Cells Therapy
NeuroGenesis and Hadassah Medical Center announced highly positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of […]
TG Therapeutics Reports Ublituximab Outperforms Sanofi Genzyme’s Aubagio in Relapsing Forms of MS in Two Phase 3 Trials
TG Therapeutics announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab […]
Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection
SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients […]
OMRF Receives $3.7 million for Autoimmune Disease Research
The National Institutes of Health has awarded the Oklahoma Medical Research Foundation $3.7 million to continue research on Sjögren’s syndrome, […]
Indiana University & Eli Lilly Ink $5m Research Pact for Patient-Centric, Autoimmune Disease Targets
Indiana University (IU) School of Medicine and Eli Lilly have come together to transform how university research and pharmaceutical companies […]
Hansa Biopharma Reports Phase 2 Data of Imlifidase in Patients with Severe anti-GBM Antibody Disease
Hansa Biopharma reported data from an investigator-initiated phase 2 trial that evaluated safety, tolerability and efficacy of imlifidase in 15 […]
KU Leuven Spin-Off Possibly Has New Way to Attack Autoimmune Disease
Why would a new immunotherapy approach be cause for researchers to reconsider Type 1 diabetes and its treatment? Perhaps a […]
Corbus’ Lenabasum Fails to Meet Endpoints in Phase 3 Systemic Sclerosis Trial
Corbus Pharmaceuticals announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic […]
Connect Biopharma Connects to $115m Series C to Progress Autoimmune Disease Drug Candidates
Sino-American biotech Connect Biopharma has collected $115 million in Series C financing led by a new investor, RA Capital Management […]
